Safety Study of Erythropoietin (EPO) in Parkinson's Disease
Safety Study of Erythropoietin (EPO) in Parkinson's Disease
The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is
 safe in the treatment of patients with Parkinson's Disease.
After onset of Parkinson's Disease (PD)- in spite of the use of medications that constitute
 the symptomatic treatment- the disease is worsens with an inevitable progression, thus
 causing complications that lead to the loss of patient´s manual skills and independent gait.
 At present, the treatment of PD with the use of medications is based on dopamine precursors
 and dopaminergic agonists but as the disease advances, other symptoms that do not respond to
 dopaminergic stimulation do appear.

 For this reason, it is a priority to find a way to focus on neuroprotection during the course
 of the disease. There are evidences of neuroprotecting therapeutic alternatives in such
 substances as erythropoietin (EPO).

 Positive results on the neuroprotective/neurotrophic efficacy of EPO in neurological and
 psychiatric diseases have been obtained from treatment trials, but nevertheless, it is
 indispensable demonstrate that with the proposed medication doses it's well tolerated by PD
 patients.
Inclusion Criteria:

 -  Hohen and Yahr´s Scale between I and III

 -  One or more years of evolution of PD,

 -  Good response to levodopa (more that 30 % of change)valued in motor UPDRS

 -  An acceptable general health status,

 Exclusion Criteria:

 -  Chronic psychiatric or other neurological diseases.

 -  Previous polyglobulin

 -  Hematocryte, same or inferior to 50